731 completed, 331 recruiting, 192 unknown, 177 terminated. 575 Phase 2, 503 Phase 1, 312 Not applicable, 126 Phase 3, 35 Early Phase 1.
Follow Hematologic Neoplasms: new trials by email Literature Review of Hematologic Neoplasms trials Research Report on Hematologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aberrant Expression of CD56 in Patients With Hematologic Malignancies. CD56 - Hematologic Malignancies | Recruiting | Asmaa Hassan mohamed Abdel Mawjoud | 38 | 2027-03-20 | 2026-03-18 | |
| Symptom Monitoring and Management Intervention After CAR-T WAYPOINT - Chimeric Antigen Receptor T-cell Therapy, Hematologic Malignancy | Not applicable | Not yet recruiting | Massachusetts General Hospital | 65 | 2027-03-01 | 2026-10-23 |
| A Study of Rusfertide in Adults With Polycythemia Vera in China Rusfertide - Polycythemia Vera | Phase 2 | Not yet recruiting | Takeda | 24 | 2027-03-01 | 2026-08-28 |
| Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies C9/CD5CAR/IL-15 NK cells, Rituximab, Fludarabine - Hematological Malignancies | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 70 | 2027-02-28 | 2026-08-20 |
| WELL-MPN: A Digital Lifestyle App for Patients With MPNs WELL-MPN Digital App - Myeloproliferative Neoplasms (MPNs) | Not applicable | Not yet recruiting | Brigham and Women's Hospital | 75 | 2027-01-01 | 2026-09-29 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Adoption of Audio Recording in the Outpatient Supportive Care Center Communication Intervention, Questionnaire Administration - Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm | Not yet recruiting | M.D. Anderson Cancer Center | 200 | 2026-12-30 | 2026-07-16 | |
| Dose-Escalation/Expansion Study of iMagic in Relapsed/Refractory Hematologic Malignancies iMagic Injection (IMV101), iMagic Injection (IMV102) - Relapsed/Refractory Hematologic Malignancies | Early Phase 1 | Not yet recruiting | Suzhou Immunofoco Biotechnology Co., Ltd | 30 | 2026-12-10 | 2026-11-04 |
| Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated - Hematologic Malignancy, Acute Leukemia | Not applicable | Not yet recruiting | Ossium Health, Inc. | 300 | 2026-12-01 | 2026-09-10 |
| variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway Chronic Lymphocytic Leukemia, Haematological Malignancy | Not yet recruiting | The Royal Wolverhampton Hospitals NHS Trust | 130 | 2026-12-01 | 2026-09-15 | |
| Wearable Data for Personalized Prognostication in Cancer: A Registry Protocol Non-Interventional Study - Hematopoietic Neoplasm, Malignant Solid Neoplasm | Not yet recruiting | City of Hope Medical Center | 1200 | 2026-12-01 | 2026-07-08 | |
| A Study to Better Understand the Diagnosis and Treatment of Polycythaemia Vera No Intervention - Polycythemia Vera | Not yet recruiting | Takeda | 90 | 2026-12-01 | 2026-10-09 | |
| MACE and BTK Inhibitors ibrutinib, Acalabrutinib, Zanubrutinib - Hematologic Cancer, MACE | Phase 4 | Not yet recruiting | University Hospital, Caen | 10000 | 2026-12-01 | 2026-11-06 |
| Micro Assays for HemATology Malignancies Antibody Treatment blood sampling - Hematological Malignancy | Not applicable | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 166 | 2026-12-01 | 2026-10-29 |
| Lanoracopan to Prevent Acute GVHD Following Haploidentical Peripheral Blood Stem Cell Transplantation: A Prospective Multicenter Single-Arm Exploratory Study Lanoracopan, Anti-thymocyte globulin (ATG), Calcineurin inhibitor (Cyclosporine or Tacrolimus) - Hematologic Malignancies, Haploidentical Peripheral Blood Stem Cell Transplantation | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 30 | 2026-12-01 | 2026-11-09 |
| Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers Cyclophosphamide, Busulfan, Fludarabine - Core Binding Factor Alpha Subunits, Hematologic Neoplasms | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 102 | 2026-11-18 | 2026-11-13 |
| High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting Therapy High-dose inactivated influenza vaccine, Standard-dose inactivated influenza vaccine - Hematologic Malignancy, Influenza | Phase 2 | Recruiting | Sung-Han Kim | 60 | 2026-11-02 | 2026-11-09 |
| Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression | Not yet recruiting | Odense University Hospital | 50 | 2026-11-01 | 2026-10-23 | |
| Phase 2 Study of Oral Epetraborole in Adults With Polycythemia Vera Epetraborole, Placebo - Polycythemia Vera (SNOMED CT: 109992005) | Phase 2 | Not yet recruiting | AN2 Therapeutics, Inc | 75 | 2026-11-01 | 2026-10-23 |
| CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation Hematopoietic Cell Transplantation, Cyclophosphamide, Tacrolimus - Graft -Versus-host-disease | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 72 | 2026-11-01 | 2026-09-08 |
Showing 20 of 1768. Sign in to see all of them.
Leukemia, Myeloid, Acute (280) · Polycythemia Vera (277) · Multiple Myeloma (250) · Leukemia (231) · Lymphoma (229) · Myelodysplastic Syndromes (223) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (212) · Primary Myelofibrosis (211) · Myeloproliferative Disorders (192) · Leukemia, Lymphocytic, Chronic, B-Cell (178) · Neoplasms (176) · Thrombocythemia, Essential (175) · Lymphoma, Non-Hodgkin (167) · Hodgkin Disease (145)
Hemic and Lymphatic Diseases (1766) · Neoplasms by Site (1755) · Hematologic Diseases (1703) · Neoplasms (1592) · Neoplasms by Histologic Type (647) · Immune System Diseases (598) · Immunoproliferative Disorders (514) · Bone Marrow Diseases (502) · Lymphoproliferative Disorders (490) · Lymphatic Diseases (475) · Pathological Conditions, Signs and Symptoms (470) · Pathologic Processes (411) · Hemorrhagic Disorders (367) · Disease Attributes (335)
Cyclophosphamide (124) · fludarabine (90) · fludarabine phosphate (81) · Tacrolimus (65) · Mycophenolic Acid (62) · Whole-Body Irradiation (62) · Busulfan (57) · Methotrexate (41) · Melphalan (39) · Peripheral Blood Stem Cell Transplantation (39) · ruxolitinib (37) · Antilymphocyte Serum (36) · Cyclosporine (29) · Thiotepa (27) · Azacitidine (25)
M.D. Anderson Cancer Center (119) · National Cancer Institute (NCI) (73) · Fred Hutchinson Cancer Center (47) · City of Hope Medical Center (29) · Novartis Pharmaceuticals (29) · St. Jude Children's Research Hospital (23) · Mayo Clinic (22) · Dana-Farber Cancer Institute (18) · Assistance Publique - Hôpitaux de Paris (16) · Massachusetts General Hospital (16) · Memorial Sloan Kettering Cancer Center (15) · University of California, San Francisco (15) · Duke University (14) · Incyte Corporation (14) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (14)
United States (1030) · France (186) · China (161) · Italy (149) · Canada (107) · Germany (104) · United Kingdom (102) · Spain (99) · Australia (64) · Belgium (61) · Netherlands (55) · Israel (43) · Poland (40) · Turkey (Türkiye) (38) · South Korea (37)
Neal Flomenberg, MD (7) · Ronald Hoffman, MD (7) · Alessandro Rambaldi, MD (6) · Christopher G Kanakry, M.D. (6) · John Mascarenhas, MD (6) · Jorge Cortes, MD (6) · Matthew Krebs, Dr (6)
PMID 32499241, PMID 23065508, PMID 23524640, PMID 29419434, PMID 33795208, PMID 34515338, PMID 41485109, PMID 12171484, PMID 19282026, PMID 23802653, PMID 26408225, PMID 29171820, PMID 29246923, PMID 29396713, PMID 29674506, PMID 29958797, PMID 30904387, PMID 32160294, PMID 32416453, PMID 32463741, PMID 33275766, PMID 35661166, PMID 36991547, PMID 37132225, PMID 37713090, PMID 37960969, PMID 38052709, PMID 38110653, PMID 39155155, PMID 39172760, PMID 39606939, PMID 39863139, PMID 40090350, PMID 40313042, PMID 40332715, PMID 40631904, PMID 40775758, PMID 40864183, PMID 41313549, PMID 41886220, PMID 41890273, PMID 42299486, PMID 42561120, PMID 42669079, PMID 42803498, PMID 5449164, PMID 10091805, PMID 10204198, PMID 10515382, PMID 10573044
U10CA180820 (21), U24CA196172 (20), P30CA015704 (18), P30CA033572 (15), 2023 (14), P30CA015083 (12), 2017 (9), 2025 (9), P01CA018029 (9), 2014 (7), P01CA108671 (7), P30CA016672 (7), 2016 (6), P30CA006973 (5), UG1CA189955 (5)